Piroxicam vs Dexamethasone for Glioblastoma: Which Preserves Immune Function?

Glioblastoma is one of the hardest cancers to treat. Even with surgery, radiation, and chemo, patients live about 15 months on average. But there is something that does not get talked about enough: the drugs used to manage symptoms might actually be hurting the immune system.

Dexamethasone, a strong corticosteroid, is standard for glioblastoma patients. It reduces brain swelling and helps with chemo side effects. It works. The catch is that dexamethasone also suppresses T cells. In a cancer where the immune system is already running on fumes, that extra suppression matters. Studies have found that high-dose dexamethasone (over 8 mg/kg) is linked to shorter survival in both animals and humans.

So the real question is whether there is a drug that can do the same job without shutting down the immune response.

Piroxicam vs. Dexamethasone in the Lab

A group of researchers decided to test piroxicam, an NSAID commonly used for arthritis and inflammatory pain, against dexamethasone in a controlled lab setting. They grew two glioblastoma cell lines, U-87 MG and A-172, and co-cultured them with human immune cells to compare how each drug affected immune cell survival and activity.

The results were clear.

Dexamethasone Suppressed Immune Cells. Piroxicam Did Not.

Dexamethasone significantly reduced PBMC growth at every concentration tested. Piroxicam, at 3, 14, and 30 micromolar doses, had no negative effect on cell proliferation. When the researchers compared T cells with and without stimulation, dexamethasone caused more suppression after TCR activation, which suggests it directly interferes with the signaling T cells need to multiply. Piroxicam left that signaling alone.

Piroxicam Protected Immune Cells Against Both Tumor Lines

The team co-cultured PBMCs with U-87 MG and A-172 cells and measured how well the immune cells survived. Dexamethasone offered no protection. Piroxicam did, significantly, against both cell lines, and higher doses gave stronger protection.

Cell Cycle Tells a Different Story

Dexamethasone trapped PBMCs in the G0/G1 phase, which essentially puts a stop to cell division. Piroxicam did not do this to immune cells. When the researchers looked at tumor cells instead, piroxicam lowered the number of A-172 cells in the G2/M phase, which could mean the drug is interfering with cancer cell division.

Metabolism and Cytokines

LDH Activity as a Metabolic Signal

LDH is an enzyme central to glycolysis, the energy pathway that fast-growing cells rely on, including both tumors and activated T cells. Piroxicam-treated PBMCs showed a clear increase in LDH activity when grown alongside glioblastoma cells. That is a good sign: the immune cells were metabolically active.

At the same time, piroxicam reduced LDH activity in U-87 MG cells directly. That pattern has shown up with other NSAIDs before — diclofenac and ibuprofen both suppress glycolysis in glioma cells. High lactate in the tumor environment is known to dampen T cell function, so if piroxicam lowers tumor metabolism, that is a second pathway worth watching.

TGF-Beta Shifted Slightly

TGF-beta is one of the main immunosuppressive molecules in glioblastoma. It helps tumors dodge immune detection. Piroxicam partially lowered TGF-beta in both cell lines, though the numbers did not reach significance. No meaningful changes were seen in IFN-gamma.

The cytokine data are suggestive rather than definitive. But they line up with the rest of the picture: piroxicam nudges the environment away from suppression.

Antioxidant Measures Stayed Steady

SOD3 activity and total antioxidant capacity did not change much between the treated and untreated groups. Piroxicam did not appear to stress the immune cells oxidatively, which is good news from a safety angle.

Why This Matters

Glioblastoma treatment depends on the immune system being able to mount some kind of anti-tumor response. Immunotherapy, checkpoint inhibitors, and cancer vaccines are all being explored. But if a patient is on dexamethasone at the same time, those treatments are working uphill.

Dexamethasone suppresses T cell growth, blocks cell cycle progression, and reduces cytokine output. It is a blunt instrument. Piroxicam leaves T cells alone, protects them from tumor suppression, and may even put the brakes on cancer cell metabolism.

This is not an isolated finding. NSAIDs have been linked to lower risk of breast, prostate, colorectal, and ovarian cancers. In glioblastoma specifically, drugs like diclofenac and ibuprofen have already been shown to slow glioma cell growth. This study adds piroxicam to that list and brings a new angle into view: immune protection.

The Catch

This was an in vitro study. The drug concentrations in a dish may not match what happens in a living human brain. Clinical trials are needed before anything changes in practice. NSAIDs also carry their own baggage – gastrointestinal bleeding and cardiovascular risk being the main ones. The risk-benefit calculation in glioblastoma patients would need careful handling.

Still, the direction is worth paying attention to. Piroxicam deserves a proper clinical look as a potential dexamethasone alternative in glioblastoma care. If the results hold up, it could change how we handle supportive care for one of the bleakest cancers we deal with.

Key Takeaways

• Dexamethasone, standard in glioblastoma care, suppresses T cell proliferation and immune function
• Piroxicam did not suppress immune cells and protected them against two glioblastoma cell lines
• Piroxicam boosted LDH activity in co-cultured PBMCs, suggesting preserved metabolic function
• Piroxicam cut LDH activity in U-87 MG tumor cells, hinting at metabolic interference
• TGF-beta dropped partially with piroxicam, though not statistically significant
• Clinical studies are needed to see if piroxicam can replace dexamethasone in patients